- Revenue guidance raised to $230-240 million for 2017, from $195-205 million
- Guidance for Cologuard tests to be completed during 2017 increased to at least 550,000 tests, from at least 470,000
- 11,000 additional providers ordered Cologuard for the first time during the second quarter, and insurance coverage expanded to 86 percent of target population
MADISON, Wis., July 25, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $57.6 million and completed approximately 135,000 Cologuard tests during the quarter ended June 30, 2017. Second-quarter 2017 revenue and completed Cologuard test volume grew 172 percent and 149 percent from the same period of 2016, respectively.